Martin Turner qualified in Medicine from University of Cambridge and St. George’s Hospital Medical School London and trained in Neurology in London and Oxford. He is Professor of Clinical Neurology & Neuroscience within Oxford University’s Nuffield Department of Clinical Neurosciences, and Consultant Neurologist to the John Radcliffe Hospital in Oxford. His PhD, under the supervision of Professor Leigh at King’s College London, applied ligand PET to explore the then emerging concept of brain pathology in sporadic and familial cases of MND. His subsequent research has been in the development of biomarkers from neuroimaging (MRI and MEG) and biofluid assays, to accelerate therapy discovery. He has been the recipient of both Medical Research Council Clinician Scientist and Senior Clinical Fellowships, the ENCALS Investigator Award and the Royal College of Physicians Graham Bull Prize. He chairs the Research Committee of the Association of British Neurologists.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.